222 related articles for article (PubMed ID: 18181675)
1. HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab.
O'Malley FP; Thomson T; Julian J; Have C; Cosby R; Gelmon K; Andrulis I; Whelan T
Arch Pathol Lab Med; 2008 Jan; 132(1):61-5. PubMed ID: 18181675
[TBL] [Abstract][Full Text] [Related]
2. Concordance between central and local laboratory HER2 testing from a community-based clinical study.
Reddy JC; Reimann JD; Anderson SM; Klein PM
Clin Breast Cancer; 2006 Jun; 7(2):153-7. PubMed ID: 16800975
[TBL] [Abstract][Full Text] [Related]
3. Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy.
Diaz NM
Cancer Control; 2001; 8(5):415-8. PubMed ID: 11579337
[TBL] [Abstract][Full Text] [Related]
4. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
[TBL] [Abstract][Full Text] [Related]
5. Chromogenic In Situ Hybridisation Test for Breast Cancer Patients with Equivocal IHC Results--a Study from Iran.
Mehrazma M; Kalantari E; Rezvani H; Bahar B; Basi A; Razavi SM; Rakhshani N
Asian Pac J Cancer Prev; 2015; 16(17):7695-700. PubMed ID: 26625783
[TBL] [Abstract][Full Text] [Related]
6. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy.
Hofmann M; Stoss O; Gaiser T; Kneitz H; Heinmöller P; Gutjahr T; Kaufmann M; Henkel T; Rüschoff J
J Clin Pathol; 2008 Jan; 61(1):89-94. PubMed ID: 17412870
[TBL] [Abstract][Full Text] [Related]
7. [HER2 ASCO guidelines. The answer to everything?].
Burandt E; Sauter G
Pathologe; 2010 Oct; 31 Suppl 2():285-91. PubMed ID: 20740285
[TBL] [Abstract][Full Text] [Related]
8. HER2 testing in breast carcinoma: very low concordance rate between reference and local laboratories in Brazil.
Wludarski SC; Lopes LF; Berto E Silva TR; Carvalho FM; Weiss LM; Bacchi CE
Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):112-8. PubMed ID: 20930616
[TBL] [Abstract][Full Text] [Related]
9. HER2--a discussion of testing approaches in the USA.
Thor A
Ann Oncol; 2001; 12 Suppl 1():S101-7. PubMed ID: 11521714
[TBL] [Abstract][Full Text] [Related]
10. Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer.
Giltnane JM; Molinaro A; Cheng H; Robinson A; Turbin D; Gelmon K; Huntsman D; Rimm DL
Arch Pathol Lab Med; 2008 Oct; 132(10):1635-47. PubMed ID: 18834223
[TBL] [Abstract][Full Text] [Related]
11. HER2 testing in breast cancer: NCCN Task Force report and recommendations.
Carlson RW; Moench SJ; Hammond ME; Perez EA; Burstein HJ; Allred DC; Vogel CL; Goldstein LJ; Somlo G; Gradishar WJ; Hudis CA; Jahanzeb M; Stark A; Wolff AC; Press MF; Winer EP; Paik S; Ljung BM;
J Natl Compr Canc Netw; 2006 Jul; 4 Suppl 3():S1-22; quiz S23-4. PubMed ID: 16813731
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
Clay MR; Iberri DJ; Bangs CD; Cherry A; Jensen KC
Am J Surg Pathol; 2013 Jan; 37(1):120-7. PubMed ID: 23108020
[TBL] [Abstract][Full Text] [Related]
13. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
[TBL] [Abstract][Full Text] [Related]
14. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.
Roche PC; Suman VJ; Jenkins RB; Davidson NE; Martino S; Kaufman PA; Addo FK; Murphy B; Ingle JN; Perez EA
J Natl Cancer Inst; 2002 Jun; 94(11):855-7. PubMed ID: 12048274
[TBL] [Abstract][Full Text] [Related]
15. Systematic review of HER2 breast cancer testing.
Cuadros M; Villegas R
Appl Immunohistochem Mol Morphol; 2009 Jan; 17(1):1-7. PubMed ID: 18685491
[TBL] [Abstract][Full Text] [Related]
16. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab.
Dybdal N; Leiberman G; Anderson S; McCune B; Bajamonde A; Cohen RL; Mass RD; Sanders C; Press MF
Breast Cancer Res Treat; 2005 Sep; 93(1):3-11. PubMed ID: 16184453
[TBL] [Abstract][Full Text] [Related]
17. Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.
McCullough AE; Dell'orto P; Reinholz MM; Gelber RD; Dueck AC; Russo L; Jenkins RB; Andrighetto S; Chen B; Jackisch C; Untch M; Perez EA; Piccart-Gebhart MJ; Viale G
Breast Cancer Res Treat; 2014 Feb; 143(3):485-92. PubMed ID: 24395109
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.
Yosepovich A; Avivi C; Bar J; Polak-Charcon S; Mardoukh C; Barshack I
Isr Med Assoc J; 2010 Jun; 12(6):353-6. PubMed ID: 20928989
[TBL] [Abstract][Full Text] [Related]
19. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma.
Bozzetti C; Negri FV; Lagrasta CA; Crafa P; Bassano C; Tamagnini I; Gardini G; Nizzoli R; Leonardi F; Gasparro D; Camisa R; Cavalli S; Silini EM; Ardizzoni A
Br J Cancer; 2011 Apr; 104(9):1372-6. PubMed ID: 21487407
[TBL] [Abstract][Full Text] [Related]
20. Concordance of HER2 Immunohistochemistry and Fluorescence
Furrer D; Jacob S; Caron C; Sanschagrin F; Provencher L; Diorio C
Anticancer Res; 2017 Jun; 37(6):3323-3329. PubMed ID: 28551685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]